Regeneron v. Sandoz: 47-Patent EYLEA® Biosimilar Dispute Ends in Settlement
Regeneron Pharmaceuticals asserted 47 patents covering EYLEA® (aflibercept) against Sandoz’s 2 mg biosimilar in the West Virginia Northern District Court. The parties reached a private agreement resolving all claims without further litigation, filing a stipulated dismissal without prejudice after 361 days. The scale of the patent portfolio — 47 assets spanning biologics, formulation, device, and design — signals the strategic depth of Regeneron’s EYLEA® IP fortress.
47-Patent EYLEA® Fortress Tested — and Settled — by Sandoz Biosimilar Entry
On 13 September 2024, Regeneron Pharmaceuticals filed Case No. 1:24-cv-00085 in the West Virginia Northern District Court before Judge Thomas S. Kleeh, asserting infringement of 47 patents against Sandoz, Inc. The asserted portfolio spans utility patents covering aflibercept protein compositions, formulation chemistry, manufacturing processes, and medical device components, together with multiple design patents covering EYLEA® delivery devices. The targeted product was Sandoz’s 2 mg aflibercept biosimilar — a direct competitive challenge to Regeneron’s market-leading EYLEA® franchise.
The case was resolved without a merits ruling. On 9 September 2025 — 361 days after filing — the parties filed a Rule 41(a)(1) stipulation dismissing all claims and counterclaims without prejudice, with each side bearing its own legal costs. The verdict text states that Regeneron and Sandoz ‘reached an agreement that will resolve all issues between them without further litigation regarding Sandoz’s 2 mg aflibercept product,’ suggesting a confidential licensing or market-entry agreement governs the commercial relationship going forward. The dismissal is expressly ‘without prejudice to the extent specified in the parties’ agreement,’ indicating that certain rights may be preserved under the private deal terms.
Resolution in approximately twelve months is notably swift given the complexity of a 47-patent biosimilar portfolio dispute. The compressed timeline suggests the parties likely entered settlement discussions early, possibly facilitated by parallel proceedings in MDL No. 24-md-3103-TSK, to which this case was joined. What remains unknown from the public record is the commercial structure of the agreement: whether Sandoz received a launch date, a royalty-bearing licence, or an exclusion period remains confidential. The mutual cost-bearing provision, standard for negotiated biosimilar resolutions, provides no signal as to which party drove settlement.
Filing to Dismissed without Prejudice in 361 days
361 days — slightly faster than the median ANDA/biosimilar patent case at first instance
Dismissed without prejudice: what the stipulated settlement means for both parties
Rule 41(a)(1) dismissal without prejudice — claims preserved by agreement
Under Rule 41(a)(1) of the Federal Rules of Civil Procedure, parties may stipulate to dismiss an action before a final merits ruling. Here, dismissal is explicitly ‘without prejudice to the extent specified in the parties’ agreement,’ meaning the underlying patent rights and certain claim options survive. No court has adjudicated validity, infringement, or enforceability of any of the 47 patents. The case ending this way is procedurally neutral — it resolves the litigation docket but leaves the IP landscape governed by private contract.
No merits ruling — IP rights intactRegeneron’s 47-patent EYLEA® portfolio emerges unchallenged in court
Because the case was dismissed without a merits ruling, none of Regeneron’s 47 asserted patents were invalidated, found unenforceable, or ruled not infringed. The portfolio retains full presumption of validity. The ‘agreement resolving all issues’ language in the stipulation is consistent with Regeneron securing structured market-entry terms for Sandoz — typical in branded-versus-biosimilar resolutions. Regeneron’s ability to field 47 patents simultaneously signals a layered enforcement strategy that may deter future biosimilar challengers.
Portfolio validity unchallengedSandoz avoids invalidation risk but accepts negotiated market terms
Sandoz exits this litigation without a court ruling that any Regeneron patent is invalid or not infringed — but also without the freedom-to-operate certainty that a successful IPR or trial outcome would have provided. The agreement ‘resolving all issues’ regarding Sandoz’s 2 mg aflibercept product suggests Sandoz accepted commercially negotiated entry conditions rather than litigating to a dispositive ruling. For Sandoz, this avoids the cost and risk of a full biosimilar patent trial across 47 patents, but may constrain launch timing or economics under the undisclosed deal terms.
Negotiated entry — terms undisclosedAflibercept biosimilar market shaped by private deal, not public ruling
The absence of any merits ruling means competitors and follow-on biosimilar filers cannot rely on this case as precedent for challenging Regeneron’s EYLEA® patents. All 47 patents remain live enforcement tools. Other biosimilar entrants — including those in the parallel MDL 24-md-3103-TSK proceedings — must independently assess validity and infringement risk across the full portfolio. The settlement is consistent with Regeneron’s strategy of using patent thickets to manage biosimilar entry timing, a model increasingly scrutinised by regulators but not restricted by this outcome.
Patent thicket strategy intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Regeneron Pharmaceuticals, Inc. | Company | Biopharmaceutical innovator — holder of EYLEA® (aflibercept) patent portfolio, US11174283B2 and 46 further patentsSearch in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Sandoz, Inc. — generic and biosimilar pharmaceutical company pursuing 2 mg aflibercept biosimilar entrySearch in Eureka ↗ |
| Plaintiff counsel | David R. Pogue | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Carey, Douglas, Kessler & Ruby, PLLC | Law Firm | Representing Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher Cassella | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Edward T. Kole | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Elaine Herrmann Blais | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Emily L. Rapalino | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Evan Stratton Aldridge | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Grace Truong | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeffrey M. Wakefield | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Joshua Weinger | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | L. Elizabeth King | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Louis L. Lobel | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Molly R. Grammel | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Morgan Elizabeth Villers | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Timothy James Beavers | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | William M. Jay | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Flaherty Sensabaugh & Bonasso PLLC | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Goodwin Procter LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Wilentz, Goldman & Spritzer, PA | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Thomas S Kleeh | Judge | West Virginia Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation text is unusually precise in its carve-out: dismissal is ‘without prejudice to the extent specified in the parties’ agreement,’ departing from the standard unconditional without-prejudice formulation. This phrasing suggests the private agreement contains specific preserved rights or conditions — potentially a licence with defined launch windows, milestone triggers, or field-of-use restrictions — that are incorporated by reference into the court record. The mutual cost-bearing provision is consistent with a negotiated resolution in which neither party extracted a decisive litigation advantage, and the explicit reference to ‘Sandoz’s 2 mg aflibercept product’ may leave higher-concentration formulations outside the agreement’s scope.
US11174283B2 — aflibercept biologics: 47-patent EYLEA® portfolio overview
The lead asserted patent, US11174283B2, is one of 47 patents Regeneron asserted covering EYLEA® (aflibercept), a VEGF-trap fusion protein approved for treatment of wet age-related macular degeneration, diabetic macular oedema, and related retinal vascular conditions. The portfolio spans utility patents protecting the aflibercept molecule, its formulation chemistry, manufacturing and purification processes, and intravitreal delivery systems, alongside multiple design patents covering EYLEA® device aesthetics. This breadth — from composition-of-matter through to device design — reflects a deliberate lifecycle management strategy spanning filing dates from the early 2010s through to the early 2020s.
Strategically, Regeneron’s 47-patent EYLEA® portfolio represents one of the most extensive biologic patent thickets in ophthalmic pharmacology. By securing overlapping layers of protection across the molecule, formulation, manufacturing, and delivery device, Regeneron creates multiple independent infringement vectors for any biosimilar entrant to navigate. The inclusion of design patents alongside utility patents is notable: a biosimilar manufacturer who designs around the composition or formulation claims may still face device-level infringement exposure. For competitors developing aflibercept biosimilars, this portfolio demands FTO clearance across all claim categories, not merely the core biological sequence claims.
Should you run an FTO against Regeneron’s 47-patent EYLEA® portfolio?
Any company developing, filing, or commercialising an aflibercept biosimilar — whether the 2 mg reference product formulation or higher-concentration variants — should treat Regeneron’s 47-patent EYLEA® portfolio as a live enforcement risk. This case demonstrates that Regeneron is willing to assert the full breadth of its portfolio simultaneously in federal court, including design patents covering delivery devices. Even products with differentiated formulations or novel delivery systems may face exposure across the utility patent families covering manufacturing processes and purification methods. R&D teams should map their process and device designs against each patent family before IND filing.
PatSnap Eureka’s FTO Search Agent can map your product’s technical profile against all 47 asserted patents and their claim families in a single automated workflow. Eureka identifies active claims, expiry timelines, and family members across jurisdictions — critical for understanding whether process patents filed as recently as 2022 create blocking positions for your development timeline. With Regeneron’s portfolio actively enforced in MDL proceedings, Eureka’s litigation monitoring layer also flags new assertions in real time, so your IP and regulatory teams can align biosimilar launch strategy with current enforcement risk.
Run a freedom-to-operate analysis on US11174283B2 to assess your product’s exposure
Run FTO in Eureka →Similar aflibercept biosimilar and biologic patent infringement cases
Cases involving biologic patent portfolios and biosimilar entry disputes in the West Virginia Northern District Court and related MDL 24-md-3103-TSK proceedings.
What this case signals for the aflibercept biosimilar IP landscape
A 47-patent biosimilar dispute resolved in 12 months without a single merits ruling carries significant strategic signal for the biologics sector.
Patent volume as settlement leverage: 47 patents creates asymmetric litigation cost
Asserting 47 patents simultaneously imposes disproportionate defence costs on a biosimilar challenger. Even a well-resourced defendant like Sandoz faces the economic calculus of defending each patent through claim construction, validity, and infringement analysis. This structural asymmetry — common in branded biologic enforcement — consistently produces negotiated outcomes rather than merits rulings, insulating the originator’s portfolio from judicial scrutiny.
MDL coordination amplifies originator leverage in multi-biosimilar disputes
This case’s inclusion in MDL No. 24-md-3103-TSK signals that Regeneron is managing multiple parallel aflibercept biosimilar actions under coordinated judicial oversight. MDL consolidation can accelerate settlement by surfacing consistent claim construction positions early. For biosimilar filers, MDL participation may limit independent litigation strategy and increase pressure to reach bilateral deals before bellwether rulings issue.
Regeneron v Sandoz — key questions answered
The case was dismissed without prejudice on 9 September 2025 after the parties reached a private agreement resolving all issues regarding Sandoz’s 2 mg aflibercept product. No merits ruling was issued on any of the 47 asserted patents. Each party agreed to bear its own costs and attorneys’ fees under the Rule 41(a)(1) stipulation.
Regeneron asserted 47 patents in Case No. 1:24-cv-00085. The portfolio spans utility patents covering aflibercept protein compositions, formulation chemistry, manufacturing and purification processes, and intravitreal delivery systems, as well as multiple design patents covering EYLEA® delivery devices and packaging components.
This non-standard without-prejudice formulation indicates that the private settlement agreement between Regeneron and Sandoz contains specific preserved rights or conditions. Unlike a standard without-prejudice dismissal — which unconditionally allows re-filing — this language suggests the parties’ agreement defines the circumstances under which claims may or may not be reasserted, likely tied to Sandoz’s compliance with the deal terms.
MDL No. 24-md-3103-TSK is a Multi-District Litigation docket before Judge Thomas S. Kleeh coordinating multiple patent infringement actions by Regeneron against different biosimilar filers of aflibercept products. Case No. 1:24-cv-00085 against Sandoz was consolidated into this MDL. MDL coordination typically facilitates consistent claim construction rulings and may accelerate settlement by increasing visibility into litigation risk across all consolidated defendants.
No. Because the case was dismissed without a merits ruling, no court adjudicated the validity, enforceability, or infringement of any of Regeneron’s 47 asserted patents. The patents retain their full statutory presumption of validity. Other biosimilar filers — including those in the parallel MDL proceedings — cannot rely on this outcome as precedent and must independently challenge each patent through IPR, district court litigation, or negotiated resolution.
PatSnap Eureka searches patents and litigation data to answer instantly.